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Abstract 
Zonulin protein is a haptoglobin precursor and functions to modulate the permeability of tight junctions 
between enterocytes. Local inflammation or systemic inflammation can trigger zonulin expression. While 
the increased zonulin level causes an increase of intestinal permeability and entrance of foreign antigens, 
the latter can increase insulin resistance and inflammation. Polycystic ovarian syndrome affects women 
during their reproductive age characterized by hyperinsulinemia and/or hyperandrogenemia and 
associated with infertility problems. Changes in gut permeability such as irritable bowel syndrome are 
often found in PCOS patients. While metformin increases insulin mediates glucose uptake and, acts as an 
insulin-sensitizing drug used to treat PCOS patients is recently discovered to reshape intestinal bacteria 
and hence may affect intestinal action. This study was designed to find any association between zonulin 
level and other parameters in PCOS patients and to find metformin treatment effects on zonulin in PCOS 
patients. Thirty-one newly diagnosed PCOS women agree to take metformin 850 mg twice daily for three 
months and, and to give fasting serum samples to measure zonulin, FSH, LH, total testosterone, free 
testosterone, SHBG, fasting insulin, and fasting serum glucose before and after treatment. The free 
testosterone and zonulin are determined by the ELISA technique while the other parameters are 
determined by the Cobas technique. According to patients’ Homeostatic Model Assessment (HOMA-IR), 
the Patients were divided into two sub-groups: the first group consisting of those with initial HOMA-IR less 
than two and the second group was those of an initial HOMA-IR of between two to four. Whereas the first 
group showed no significant response to treatment, the second group showed a better response to 
metformin treatment, as demonstrated by their LH, total testosterone, free testosterone, fasting insulin, 
zonulin, and glucose levels. These parameters markedly improved after metformin treatment with p-
values of 0.08, 0.09, 0.07. 0.04, 0.01 and 0.06, respectively.  
©2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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The polycystic ovarian syndrome can affect women during their reproductive age at an incidence rate of 
3-10 % and characterized by sex hormone imbalance [1,2]. Irregular menstrual cycle, polycystic ovary 
morphology, and hirsutism are the most frequent symptoms, with features of infertility and insulin 
resistance [3,4]. Insulin resistance and obesity play roles in PCOS pathophysiology [5,6]. Insulin resistance 
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gives rise to hyperinsulinemia [7], which directs ovarian steroidogenic enzymes to produce more androgen 
and abolish ovulation [8,9]. Therefore, insulin-resistant PCOS patients show more metabolic lipogenic 
changes, and abnormal steroidogenesis because of a decrease in insulin signaling, while non-insulin 
resistant PCOS patients show abnormality in steroidogenesis only [10,11]. The HOMA-IR is a technique used 
to assess the β-cell function and insulin resistance from basal glucose and insulin and it equalizes ((Fasting 
Insulin multiplied by Fasting glucose) divided by 22.5), normal HOMA IR is 1 [12,13]. Insulin resistance 
occurs when fasting insulin is HOMA-IR>2 [14]. 
Zonulin is a haptoglobin precursor that has a molecular-weight of 47 kDa and modulates the 
permeability of tight junction (TJ) between cells of the digestive tract [15,16]. An increase in zonulin is 
associated with an increase in gut permeability. Zonulin expression is triggered by either local inflammation 
or systemic sub-clinical inflammation [17] and is suggested to have a role in the production of metabolic 
syndrome and insulin resistance [18]. In PCOS women, zonulin is correlated with insulin resistance and the 
severity of the menstrual disorder [19]. Moreover, irritable bowel syndrome and chronic fatigue syndrome, 
two conditions common in PCOS are linked to an increase in gut permeability [20,21]. Metformin drug used 
in PCOS treatment can decrease hepatic gluconeogenesis by different mechanisms [22]: delay intestinal 
glucose absorption [23], reshape microbiota in the intestine [24,25], increase insulin-mediated glucose 
uptake in the liver, visceral fat, and muscle [26], and stimulates insulin signaling pathway in human 
granulosa cells and other cells of the body [27]. This insulin-sensitizing drug, promises PCOS patients, may 
play a role in zonulin level and gut permeability. Therefore, the study is designed to find the metformin 
effects on zonulin level in PCOS patients and its association with other parameters. 
Experimental  
Thirty-one newly diagnosed PCOS women according to Rotterdam criteria are included in this study. 
Patients with adrenal dysfunction, thyroid dysfunction, diabetics, and those on oral contraceptives are 
excluded from the study. Fasting insulin, fasting glucose, FSH, LH, testosterone, free testosterone, SHBG, 
and serum zonulin are measured before and after intake of metformin (Bigomet®), 850 mg twice daily for 
three months. The research plan was approved by the Scientific Committee of the College of Medicine, 
Tikrit University, on 24/October/ 2018. The parameters of FSH, LH, total testosterone, SHBG, and insulin are 
determined by Cobas technique (Cobas e 411 systems); fasting serum glucose was determined by 
Cobas c 311analyzers. Serum zonulin has been determined according to “Human zonulin ELISA kit Cat NO. 
MBS2607261 “supplied by Mybiosource/USA Company. Free testosterone is determined by the ELISA 
technique. Statistical analysis performed by SPSS and the significant changes was considered when p-value 
less 0.05. The patients are divided into two subgroups according to their initial Homeostatic Model 
Assessment (HOMA-IR) that is determined before starting metformin treatment. 
First group 
Sixteen patients have initial HOMA-IR less than two, eleven of them have primary infertility and only five 
women have secondary infertility, and their mean age was 28.81 years. 
Second group 
Fifteen patients have initial HOMA-IR two to four, twelve of them have primary infertility and only three 
of them have secondary infertility, and their mean age was 26.93 years. 
Results and discussion 
First group, those of initial HOMA-IR <2, did not show any significant difference in any of the parameters 
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that measured including BMI, FSH, LH, testosterone, free testosterone, SHBG, fasting insulin, fasting 
glucose, HOMA IR, and zonulin as seen in Table 1. 
Table 1. Statistical analysis of parameters and zonulin before metformin therapy in PCOS 
with initial (before treatment) HOMA-IR <2 
Initial HOMA-IR<2 Mean +sd p-value 
BMI 
Before  28.26+5.93 
0.4 





































Table 2. Statistical analysis of parameters and zonulin before and after metformin therapy 
in PCOS with initial (before treatment) HOMA-IR = 2-4 
Initial HOMA-IR=2 – 4 Mean +SD p-value 
BMI 
Before  28.95+8.55 
0.3 





































    *p-value less than 0.05  
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The second group those of initial HOMA-IR 2-4 (insulin resistance group), showed better response to 
metformin treatment (Table 2). This group exhibits a marked decrease in LH, total testosterone, free 
testosterone, fasting glucose with a p-value of 0.08, 0.09, 0.07 and 0.06 respectively, and a significant 
decrease in fasting insulin, HOMA-IR, and zonulin with p-values of 0.04, 0.02 and 0.01 respectively. 
 The study showed no change in body mass index (BMI) (Tables 1 and 2), which is in agreement 
with Sharma et al 2019 study [28]. It is well known that most PCOS women are obese, and they have an 
increase in blood volume and the volume of distribution of any drug [29]. Therefore, a higher dose of any 
drug is required to do equivalent action in non-obese patients [30].  
The first group, those of initial HOMA-IR less than two (Table 1), exhibited no significant decrease in 
their HOMA-IR and fasting glucose after metformin treatment, while the second group, those of initial 
HOMA-IR two to four (Table 2) exhibited a significant decrease in HOMA-IR after the end of three months 
therapy with a p-value of 0.04, and a marked decrease in fasting glucose, with a P-value of 0.06. This result 
agrees with the study of Nawrocka and Starczewski, who showed that metformin can significantly decrease 
HOMA-IR only in insulin-resistant PCOS patients [31]. Moreover, the first group (Table 1) showed no 
significant changes in zonulin value after treatment, while the second group (Table 2), showed a significant 
decrease in zonulin with a P-value of 0.01, suggesting that metformin can decrease zonulin in insulin-
resistant patients with no menstrual disturbances. Ilhan and Yildizhan study suggested that zonulin is a 
pathogenic novel biomarker in PCOS women and there is a strong correlation between HOMA-IR and 
zonulin in PCOS patients [32]. Also, Zhang et al suggested that zonulin plays a role in PCOS pathogenesis 
and can be used as a marker for detection of the severity of disease and in the prognosis of PCOS treatment 
[19]. This is obvious, especially that increase zonulin leads to alteration in gut permeability, decrease the 
integrity of the intestinal barrier allowing an excess of the infectious agent and dietary antigen to facilitate 
mucosal immune elements such as IL-6 which can lead to insulin resistance [33]. We proposed that the 
metformin effect on zonulin is related to the antibiotic effect of metformin on the gut and modulation of 
intestinal microbiota. However, the first group of those of initial (HOMA-IR <2) exhibited no changes in 
zonulin value as there is no difference in gut permeability and microbiota composition before and after 
treatment, as non-insulin resistance associated with no alteration in intestinal permeability. This agrees to a 
certain degree with Cetin’s study conclusion, who included non-obese, normal HOMA-IR PCOS patients in 
his study and suggested that insulin resistance is not triggered if there is integrity in the gut permeability 
[34]. It seems that this study is the first study to show the effect of metformin on zonulin in PCOS patients. 
We found that metformin can decrease zonulin in insulin-resistant PCOS patients with no menstrual 
irregularities and not prone to have diabetes, and we suggest that metformin effects on zonulin are not 
related to insulin-sensitizing activity but may be due to the modulation of intestinal bacteria. 
Testosterone and free testosterone showed no significant decrease in the non-insulin resistant group 
(Table 1) p-value 0.13 and 0.12 respectively, while the second group showed a marked but insignificant 
decrease in total testosterone p-value 0.09 and free testosterone p-value 0.07. This result agrees with 
Baqer et al study in 2018 when they administer metformin 500 mg three times for three months and 
showed an insignificant decrease in total testosterone [35]. Metformin can suppress androgen production 
by its action on the ovary and adrenal gland and increase SHBG production by the liver [23]. Different 
studies revealed that metformin causes a reduction in androgen, an increase of SHBG, and a restoration of 
the normal menstrual cycle [36-40] but this study reveals a slight insignificant increase in SHBG in both 
groups, which agree with Singh et al. study who show no significant decrease in serum testosterone, fasting 
plasma glucose and BMI with a significant decrease in HOMA-IR, after intake of metformin 500 mg twice 
daily for 3 months [41]. On the other hand, Upadhyaya and Rehan study has reported that women of PCOS 
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with hyperinsulinemia show a significant reduction in testosterone in compare to the normo-insulinemic 
group after metformin treatment and they suggested that hyperinsulinemic, normo-androgenic PCOS is a 
favorable condition for metformin response [42], also Moghetti et al reveal that metformin responders 
usually had higher fasting plasma insulin [43]. Concerning the level of LH, the second group (Table 2) 
showed a decrease in LH with a p-value of 0.08, while the first group of less insulin-resistant patients (Table 
1) exhibited a p-value of 0.25. This is attributed to that the hyperinsulinemia increased androgen 
production by augmenting the LH effect for androgen production, while metformin can reverse this by 
decrease insulin level [44]. 
Conclusions 
Metformin alone does not affect body mass index within three months of treatment and has no effect 
on insulin level in non-insulin resistant PCOS patients, but can decrease insulin in insulin-resistant PCOS 
patients. Concerning zonulin, the significant decrease in zonulin in women with higher insulin resistance 
may be attributed to the metformin effect on intestinal bacterial distribution. These results give rise to 
conclude that patients with higher HOMA-IR value before treatment (insulin resistant) are better 
metformin responders. 
Conflict of interest: Authors declare no conflict of interest.  
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